The authors were investigating the metabolism of prostaglandin F2α in human early placenta, in in vitro incubation experiments. They have identified both major metabolites, 15-keto-PGPGF2αand 15-keto-13, 14 dehydro PGPGF2α. They have examined the change in the percentage of these, taken as a function of time. They have established that the main site of inactivating the endogenous PGPGF2α, is the early human placenta. They suppose that the considerable Pg-inactiviting effect of the placenta has a part which acts as a protecting mechanism in preventing the uterotonic influence of the endogenous prostaglandins.
- Human placenta
- In vitro
- Prostaglandin F
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Endocrinology, Diabetes and Metabolism